Sequent Scientific posts 94% profit jump, merger progressing

Sequent Scientific reported Q1 revenues of ₹4,414 million, up 13.1% year-on-year, and profit of ₹176 million, a 93.7% increase.

Combined performance with merger partner Viyash shows revenues of ₹7,941 million and adjusted EBITDA of ₹1,290 million.

The merger with Viyash Life Sciences is proceeding as planned, with shareholder meetings scheduled for August 30, 2025, and completion expected within 12-15 months.